CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model
Abstract Background CD47/SIRPα axis is recognized as an innate immune checkpoint and emerging clinical data validate the interest of interrupting this pathway in cancer, particularly in hematological malignancies. In preclinical models, CD47/SIRPα blocking agents have been shown to mobilize phagocyt...
Main Authors: | , , , , , , , , , , , , |
---|---|
Formato: | Artigo |
Idioma: | English |
Publicado em: |
BMC
2022-05-01
|
Colecção: | Experimental Hematology & Oncology |
Assuntos: | |
Acesso em linha: | https://doi.org/10.1186/s40164-022-00279-w |